The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity.
Open accessAbstract
Construction of a bispecific single-chain antibody derivative is described that consists of two different single-chain Fv fragments joined through a Gly-Ser linker. One specificity of the two Fv fragments is directed against the CD3 antigen of human T cells and the other is directed against the epithelial 17-1A antigen; the latter had been found in a clinical trial to be a suitable target for antibody therapy of minimal residual colorectal cancer. The construct could be expressed in CHO cells as a fully functional protein, while its periplasmic expression in Escherichia coli resulted in a nonfunctional protein only. The antigen-binding properties of the bispecific single-chain antibody are indistinguishable from those of the corresponding univalent single-chain Fv fragments. By redirecting human peripheral T lymphocytes against 17-1A-positive tumor cells, the bispecific antibody proved to be highly cytotoxic at nanomolar concentrations as demonstrated by 51Cr release assay on various cell lines. The described bispecific construct has a molecular mass of 60 kDa and can be easily purified by its C-terminal histidine tail on a Ni-NTA chromatography column. As bispecific antibodies have already been shown to be effective in vivo in experimental tumor systems as well as in phase-one clinical trials, the small CD3/17-1A-bispecific antibody may be more efficacious than intact antibodies against minimal residual cancer cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This new kind of bsAb proved to be highly cytotoxic at nanomolar concentrations against various cell lines, using unstimulated human PBMCs in the absence of co-signaling. 44”
From Bispecific antibodies for cancer therapy: The light at the end of the tunnel? (2009) · cites this paper as [44]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A new method for predicting signal sequence cleavage sites
von HEIJNE, G. (1986) · Nucleic Acids Research · doi:10.1093/nar/14.11.4683 · Cited by 4,473
Pelletier, J., & Sonenberg, N. (1988) · Nature · doi:10.1038/334320a0 · Cited by 1,953
Huston, J. S., Levinson, D., Mudgett-Hunter, M., Tai, M. S., Novotný, J., Margolies, M. N., Ridge, R. J., Bruccoleri, R. E., Haber, E., & Crea, R. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.16.5879 · Cited by 1,610
pEF-BOS, a powerful mammalian expression vector
Mizushima, S., & Nagata, S. (1990) · Nucleic Acids Research · doi:10.1093/nar/18.17.5322 · Cited by 1,594
Single-Chain Antigen-Binding Proteins
Bird, R. E., Hardman, K. D., Jacobson, J. W., Johnson, S., Kaufman, B. M., Lee, S., Lee, T. T., Pope, S. H., Riordan, G. S., & Whitlow, M. D. (1988) · Science · doi:10.1126/science.3140379 · Cited by 1,522
"Diabodies": small bivalent and bispecific antibody fragments.
Holliger, P., Prospero, T. D., & Winter, G. P. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.14.6444 · Cited by 882
Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms.
Yokota, T., Milenic, D. E., Whitlow, M. D., & Schlom, J. (1992) · PubMed · Cited by 819
Cloning immunoglobulin variable domains for expression by the polymerase chain reaction.
Orlandi, R., Güssow, D., Jones, P. T., & Winter, G. P. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.10.3833 · Cited by 715
Riethmüller, G., Gruber, R., Schneider-Gädicke, E., Schlimok, G., Witte, J., Raab, R., Pichlmayr, R., Pichlmaier, H., Schmiegel, W., Buggisch, P., et al. (1994) · The Lancet · doi:10.1016/s0140-6736(94)92398-1 · Cited by 633
Self-citationHybrid antibodies can target sites for attack by T cells
Staerz, U. D., Kanagawa, O., & Bevan, M. J. (1985) · Nature · doi:10.1038/314628a0 · Cited by 492
Research works printed but not linked: 6
- [9]Staerz, U. D. & Bevan, M. J. (1986) Proc. Natl. Acad. Sci. USA 83, 1453–1457.
- [13]Hollinger, P., Prospero, T. & Winter, G. (1993) Proc. Natl. Acad. Sci. USA 90, 6444–6448.
- [16]Huston, J. S., Levinson, D., Mudgett-Hunter, M., Tai, M.-S., Novotny, J., Margolies, M. N., Ridge, R. J., Bruccoleri, R. E., Haber, E., Crea, R. & Oppermann, H. (1988) Proc. Natl. Acad. Sci. USA 85, 5879–5883.
- [18]Orlandi, R., Güssow, D. H., Jones, P. T. & Winter, G. (1989) Proc. Natl. Acad. Sci. USA 86, 3833–3837.
- [25]Szala, S., Froehlich, M., Scollon, M., Kasai, Y., Steplewski, Z., Koprowsky, H. & Linnebach, A. J. (1990) Proc. Natl. Acad. Sci. USA 87, 3542–3564.
- [30]Brinkmann, U., Reiter, Y., Jung, S., Lee, B. & Pastan, I. (1993) Proc. Natl. Acad. Sci. USA 90, 7538–7542.
Cited by
Sorted by citations
Items 301–351 of 351
Expression of Chemokines in the Periplasmic Space of E. coli
Pfirstinger, J., & Mack, M. (2003) · Humana Press eBooks · doi:10.1385/1-59259-058-6:41 · Cited by 1
Self-citationMultiple antibody and multi-specificity approaches
(2012) · Elsevier eBooks · doi:10.1533/9781908818096.299 · Cited by 1
Pioneering Immunotherapy Agents and Their Synergy with Radiotherapy
Zhang, S.-J., Zheng, L., Cao, L., Wang, G.-R., Xiao, Y., Wu, Q., Liu, B., & Bu, L. (2025) · Springer eBooks · doi:10.1007/978-981-96-3659-4_9 · Cited by 1
Koenig, P. S., & Fuh, G. (2011) · Springer eBooks · doi:10.1007/978-3-642-20910-9_11 · Cited by 1
The research and development of bispecific antibodies
Zhao, W. (2019) · AIP conference proceedings · doi:10.1063/1.5110811 · Cited by 1
Efficient heterodimerization of recombinant bi- and trispecific antibodies
Schoonjans, R., Willems, A., Grooten, J., & Mertens, N. (2000) · Bioseparation · doi:10.1023/a:1008120203269 · Cited by 1
SPRi cytometry: sensitively sensing the sensitive side of cells
Stojanovic, I. (2016) · doi:10.3990/1.6047415 · Cited by 1
Banaszek, A. (2013) · Online Publication Service of Würzburg University (Würzburg University) · Cited by 1
(2012) · Elsevier eBooks · doi:10.1016/b978-1-907568-37-4.50029-4 · Cited by 1
Bispecific Antibodies for the Treatment of Cancer: The Challenges of Translation
Jung, G., & Große‐Hovest, L. (2014) · Springer eBooks · doi:10.1007/978-3-319-05104-8_11
Recent Developments in the Construction of Bispecific Antibodies
Helfrich, W., Kroesen, B. J., Molema, G., & de Leij, L. (1998) · Springer eBooks · doi:10.1007/978-1-4615-5619-0_10
Kopacek, A. (2009) · Kölner Universitäts PublikationsServer (Universität zu Köln)
Bifunctional Antibodies: Preclinical and Clinical Applications
Shuptrine, C. W., & Weiner, L. M. (2013) · Springer eBooks · doi:10.1007/978-1-4614-8809-5_10
Gall, F. L., Reusch, U., Bakulina, A., & Kiprijanov, S. M. (2012) · Journal of Molecular Biology · doi:10.1016/j.jmb.2012.08.028
Modificadores de la respuesta biológica en hematología
García, A. G., & Cardoso, F. P. (2001) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/s0304-5412(01)70541-0
Médicaments de haute technologie en oncologie
Étienne-Grimaldi, M.-C., Couvreur, P., Benoît, J., Fanciullino, R., Sergent, J., Miert, E. V., Pourroy, B., Meshaka, P., Brescianini, A., Corvaı̈a, N., et al. (2014) · ONCOLOGIE · doi:10.1007/s10269-014-2417-8
Advances in Bispecific Antibodies Engineering: Novel Concepts for
Duong, M. N., Klein, C., & Dumontet, C. (2015)
Kurkjian, C. D., & Ozer, H. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3764-2_43
Production of Bispecif ic and Trispecific F(ab)2 and F(ab)3 Antibody Derivatives
French, R. R. (1998) · Methods in molecular biology · doi:10.1007/978-1-59259-257-9_12
Immuntherapie gastrointestinaler Tumoren
Meyer, D., Illert, B., Timmermann, W., Thiede, A., & Waaga-Gasser, A. M. (2005) · Der Onkologe · doi:10.1007/s00761-005-0866-9
Merk, H. F. (2018) · Der Deutsche Dermatologe · doi:10.1007/s15011-018-2233-3
Investigation of HIV cure strategies in vivo in BLT humanized mice
Tsai, P. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/a6ry-q486
Engineering Biomaterial Properties for T Cell Immunotherapy
Hickey, J. W. (2019)
A Comparative Investigation of the Bispecific Antibody: Expression in Expi293F Cells and E.coli
Moazzami, R., Mirzahosaini, H., Naddafi, F., & Davami, F. (2021) · Quarterly of Horizon of Medical Sciences · doi:10.32598/hms.27.3.3478.1
Chimeric antigen receptor t cells as a living drug for cancer immunotherapy
Goswami, T. K., Sharma, A., & Sharma, G. (2021) · Indian Journal of Comparative Microbiology Immunology and Infectious Diseases · doi:10.5958/0974-0147.2021.00001.5
Faculty Opinions recommendation of Current progress in innovative engineered antibodies.
Abdiche, Y. N. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.729268838.793560915
Silver, P. A. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.732579487.793556859
Antibody‐Based Targeted T ‐Cell Therapies
Bansode, M., Deb, K., & Deb, S. (2022) · Methods and principles in medicinal chemistry · doi:10.1002/9783527827855.ch13
A novel brick for bispecific antibody construction
He, Y., Ma, H., Wang, C., Ai, Z., Wu, Q. Y., Chen, H., & Lu, D. (2023) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.26492
Identification of nonsense-mediated decay inhibitors that alter the tumor immune landscapePreprint
Cook, A. L., Sur, S., Dobbyn, L., Watson, E., Cohen, J. D., Ptak, B., Lee, B. S., Paul, S., Hsiue, E. H.-C., Popoli, M., et al. (2024) · eLife · doi:10.7554/elife.95952.1
Re-Engaging the Immune System: Immunotherapy for Neuroblastoma
Nakajima, M., & Cheung, N. V. (2024) · Pediatric oncology · doi:10.1007/978-3-031-51292-6_12
Cook, A. L., Sur, S., Dobbyn, L., Watson, E., Cohen, J. D., Ptak, B., Lee, B. S., Paul, S., Hsiue, E. H.-C., Popoli, M., et al. (2024) · eLife · doi:10.7554/elife.95952.2.sa0
Identification of nonsense-mediated decay inhibitors that alter the tumor immune landscapePreprint
Cook, A. L., Sur, S., Dobbyn, L., Watson, E., Cohen, J. D., Ptak, B., Lee, B. S., Paul, S., Hsiue, E. H.-C., Popoli, M., et al. (2024) · eLife · doi:10.7554/elife.95952.2
Generation and functional evaluation of STAb-T cells
Jiménez-Reinoso, A., Blanco, B., & Álvarez‐Vallina, L. (2025) · Methods in cell biology · doi:10.1016/bs.mcb.2025.03.010
Antibody-Redirected T-Cell Immunotherapy for Brain Tumors
Choi, B. D. (2014) · DukeSpace (Duke University)
Tumorantigene und ihre Nutzung für eine Therapie mit Antikörpern
Micheel, B. (1998) · Springer eBooks · doi:10.1007/978-3-642-80362-8_8
Yang, J., Chen, S. S., Idnani, E., Shannon, S. R., Luly, K. M., Fabilane, C. S., Wilson, D. S., Spangler, J. B., Tzeng, S. Y., & Green, J. J. (2026) · Molecular Therapy Advances · doi:10.1016/j.omta.2026.201708
Développement et évaluation d'anticorps bispécifiques dans le traitement du Myélome multiple
Fayon, M. (2019) · theses.fr (ABES) · doi:10.70675/f357d44fz13a7z4f3bza50cz18ea6c378e17
An Overview on T-Cell Engagers: The Current Position in Both the Biological and Mathematical Context
Davies, J., Brown, L., Jones, M. W., Penny, M., & Powathil, G. (2026) · Computational and Structural Biotechnology Journal · doi:10.34133/csbj.0209
B-cell precursor acute lymphoblastic leukaemia: origins, classification, and therapeutic advances
Casey, D., Gao, Z., & Boyes, J. (2026) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2026.109120
Immune Cell Engagers and “Masking Immunotherapy” for Solid Tumors: Focus on Head and Neck Cancers
Nardo, G., Lenoci, D., Lucchetta, M., Licitra, L. F., Cecco, L. D., & Cavalieri, S. (2026) · Cancers · doi:10.3390/cancers18203401
Short peptides sensitize target cells to CTL specific for the MHC class Ib molecule, H2-M3
Dabhi, V. M., & Fischer Lindahl, K. (1998) · European Journal of Immunology · doi:10.1002/(sici)1521-4141(199811)28:11
Metadata
- Authors
- Mack, M., Riethmüller, G., & Kufer, P.
- Affiliations
- Institut für Immunologie (DE)
- ORCID
- Mack, M
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 1995-07-18
- Volume
- 92
- Issue
- 15
- Pages
- 7021-7025
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC41463
- OpenAlex
- W2086146164
- Cited by
- 351
- References
- 39
- Citations by year
- 2026: 8 · 2025: 11 · 2024: 15 · 2023: 7 · 2022: 10 · 2021: 20 · 2020: 12 · 2019: 22 · 2018: 19 · 2017: 20 · 2016: 12 · 2015: 22 · 2014: 16 · 2013: 13 · 2012: 14
- FWCI
- 12.32
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Immunology and Microbiology › Immunology › Toxin Mechanisms and Immunotoxins
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein purification and stability
- Keywords
- bispecific antibodies, single-chain antibody, single-chain Fv fragments, CD3 antigen, colorectal cancer, minimal residual disease, tumor cell killing, CHO cell expression, Ni-NTA affinity purification, antibody therapy
- MeSH terms
- Amino Acid Sequence, Antibody Specificity, Antineoplastic Agents, Base Sequence, Cloning, Molecular, Escherichia coli, Immunoglobulin Fragments, Immunoglobulin Variable Region, Molecular Sequence Data, Recombinant Proteins, Tumor Cells, Cultured, Blotting, Western
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
